TABLE 1.
Phenotypic and genotypic characteristics of the strains used in this study
| Strain (n = 30) | MIC (μg/ml) ofa
: |
cyp51A genotype | Applicationb | ||
|---|---|---|---|---|---|
| ITC | VRC | POS | |||
| BMU 07945 | 0.5 | >16 | 0.5 | TR46/Y121F/T289A | Establish detection assays and validate method |
| BMU 08181 | >16 | 2 | 0.5 | TR34/L98H | |
| BMU 03908 | 16 | 0.5 | 16 | G54W | |
| BMU 02810 | 16 | 0.5 | 0.5 | G54R | |
| BMU 02731 | 16 | 1 | 0.25 | M220I | |
| BMU 07946 | 0.5 | >16 | 0.5 | TR46/Y121F/T289A | Validate method |
| BMU 07160 | >16 | 2 | 1 | TR34/L98H | |
| BMU 04835 | >16 | 8 | 1 | TR34/L98H | |
| BMU 04836 | >16 | 2 | 1 | TR34/L98H | |
| BMU 02816 | 16 | 0.5 | 0.5 | G54R | |
| BMU 02998 | 16 | 0.5 | 0.5 | G54R | |
| BMU 03941 | 16 | 1 | 16 | G54W | |
| BMU 03942 | 16 | 1 | 16 | G54W | |
| BMU 04053 | 16 | 0.5 | 16 | G54W | |
| BMU 04758 | 16 | 1 | 16 | G54W | |
| BMU 01028 | 1 | 0.5 | 0.25 | None | |
| BMU 02491 | 0.5 | 0.5 | 0.125 | None | |
| BMU 02732 | 1 | 1 | 0.125 | None | |
| BMU 02961 | 0.5 | 0.5 | 0.25 | None | |
| BMU 03968 | 0.5 | 0.5 | 0.03 | None | |
| BMU 04626 | 1 | 0.5 | 0.06 | None | |
| BMU 07722 | 0.5 | 0.5 | 0.125 | None | |
| BMU 07427 | 0.5 | 0.25 | 0.125 | None | |
| BMU 07442 | 0.5 | 1 | 0.125 | None | |
| BMU 07543 | 1 | 0.5 | 0.03 | None | |
| BMU 07544 | 0.5 | 1 | 0.125 | None | |
| BMU 07545 | 0.5 | 0.5 | 0.06 | None | |
| BMU 07446 | 0.25 | 0.5 | 0.125 | None | |
| BMU 07891 | 1 | 0.5 | 0.125 | None | |
| BMU 08016 | 0.5 | 1 | 0.125 | None | |
a
ITC, itraconazole; VRC, voriconazole; POS, posaconazole.
b
All 30 strains were used to validate the efficacy of this method in distinguishing triazole-resistant and -susceptible strains, and the first 5 triazole-resistant strains were additionally used to establish the detection assays.